Table 4.

Baseline Clinical Characteristics of Pregnant Women With Multidrug/Rifampicin-Resistant Tuberculosis, Stratified by Bedaquiline Exposure

Clinical Characteristics	Bedaquiline in Regimen n = 58 No. (%)	No Bedaquiline in Regimen n = 50 No. (%)	P Value
Age: years, mean; SD	28.7; 6.08	27.0; 6.01	.150
Hb, g/dl: mean; SD	10.4; 1.55	N = 46; 10.4; 1.65	.928
Body Mass Index (BMI): kg/m2 mean; SD	23.7; 4.70	N = 48; 24.2; 5.08	.543
TB characteristics
Culture positive at treatment initiation	42 (72%)	N = 31; (63%)	.405
Previous tuberculosis or MDR/ RR-tuberculosis	N = 35; 19 (54%)	N = 47; 19 (40%)	.265
Site of tuberculosis: pulmonary	57 (100%)	51 (100%)	NA
Chest radiograph			.923
Extensive disease	N = 51; 23 (45%)	N = 46; 22 (48%)
Resistance pattern: no (%)			1.000
RR-/Rif-mono/MDR-tuberculosis	45 (78%)	38 (76%)
Pre-XDR-/XDR-tuberculosis	13 (22%)	12 (24%)
HIV characteristics
HIV-positive, no. (%)	48 (83%)	40 (80%)	.806
HIV-positive patients on ART before MDR/RR-tuberculosis treatment started	N = 48; 37 (77%)	N = 40; 37 (90%)	.155
Baseline CD4 count, median cells/mm3 [IQR]	N = 45; 335 [138–500]	N = 36; 395 [219–540]	.352
Pregnancy characteristics
Pregnant before MDR/RR-tuberculosis treatment started	47 (81%)	42 (84%)	.802
Gestational age at treatment start: weeks, median [IQR]	23 [13–28]	20.5 [15–28]	.905
Foetal exposure to any second-line drugs: days, median [IQR]	110 [66–203]	141 [70–213]	.562
Fetal exposure to bedaquiline: days, median [IQR]	77 [28–140]	NA	NA

Abbreviations: ART, antiretroviral therapy; Hb, hemoglobin; HIV, human immunodeficiency virus; IQR, interquartile range; MDR/RR-TB, multidrug/rifampicin-resistant TB; NA, not applicable; Pre-XDR, pre-extensively drug-resistant; Rif-mono, rifampicin monoresistant; SD, standard deviation; TB, tuberculosis; XDR, extensively drug-resistant.

^aExtensive disease was classified as bilateral disease and/or cavities on chest radiograph.